Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torcetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torcetrapib SCHEMBL10041443 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL126708 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL29403162 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL7169875 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL18027496 | 0.97 | CETP (0.94) | CETP | |
| SCHEMBL12756768 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3185801 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187101 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187095 | 0.96 | CETP (0.92) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8179 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20240148913-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| CN-112274646-B | Amphiphilic protein-macromolecule conjugate delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-112274651-B | Polydopamine nano-carrier delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-112206326-B | Amino acid self-assembled nanocarrier delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| US-11549142-B2 | CETP inhibitors for therapeutic use | HOFFMANN-LA ROCHE INC. (US) | 2023-01-10 | — | — | US | claimed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-6313142-B1 | AS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR; FOR THERAPY OF ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, DYSLIPIDEMIA, HYPERBETALIPOPROTEINEMIA, HYPOALPHALIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA | PFIZER INC. | 2001-11-06 | — | — | US | claimed |
| EP-1125929-A1 | Method for making (-)-(2R,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| EP-1114031-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | claimed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | claimed |
| WO-2000017164-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | claimed |